Novartis: CAN-COVID test update
(CercleFinance.com) - Novartis has provided an update on the CAN-COVID trial in hospitalised patients with COVID-19 pneumonia and cytokine release syndrome (SRC).
The Phase III trial on canakinumab plus standard-of-care (SoC) did not meet its primary endpoint of a greater chance of patient survival without the need for invasive mechanical ventilation, or its key secondary endpoint for reducing COVID-19 mortality, relative to SoC.
Novartis has further strengthened its pandemic response efforts by working with Molecular Partners to develop two DARPin therapies for potential use against COVID-19. In addition, a Phase III trial of ruxolitinib in COVID-19 is underway with preliminary results expected by the end of the year.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The Phase III trial on canakinumab plus standard-of-care (SoC) did not meet its primary endpoint of a greater chance of patient survival without the need for invasive mechanical ventilation, or its key secondary endpoint for reducing COVID-19 mortality, relative to SoC.
Novartis has further strengthened its pandemic response efforts by working with Molecular Partners to develop two DARPin therapies for potential use against COVID-19. In addition, a Phase III trial of ruxolitinib in COVID-19 is underway with preliminary results expected by the end of the year.
Copyright (c) 2020 CercleFinance.com. All rights reserved.